Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avotermin in scar revision surgery
NCT00432211Phase 2Unknown
- Sponsor
- Renovo
- Start
- May 2006
- Primary completion
- Jul 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of avotermin in cicatrix (2 arms), sponsored by Renovo. Primary endpoints: Investigator scar assessment at 7 months, Patient scar assessment at 7 months and 1 more. Status: unknown.
02
Drugs
avotermin
03
Conditions
cicatrix
Beyond the preview
Go deeper on NCT00432211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00432211.